BridgeBio Pharma, Inc. Marketable Securities
BridgeBio Pharma, Inc. (BBIO) had Marketable Securities of $0 as of 2024-12-31, per its 10-Q filed 2025-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:MarketableSecurities · last filed 2025-08-05
- 2024-12-31: Marketable Securities $0.00.
- 2024-09-30: Marketable Securities $0.00.
- 2023-12-31: Marketable Securities $0.00.
- 2018-12-31: Marketable Securities $0.00.
| Period end | Marketable Securities |
|---|---|
| 2024-12-31 | $0.00 10-Q · filed 2025-08-05 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-12 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |